Under the strategic cooperation framework between E-Town Holdings and Fangchenggang City, representatives from the biomedicine sectors of Beijing and Guangxi have carried out in-depth exchanges. As one of the matched enterprises organized by E-Town Holdings, Genecradle Therapeutics has been deeply involved in the exchange and collaboration of the biomedicine sector between the two regions.
Recently, a delegation led by Huang Zhonghui, Member of the Leading Party Members' Group and Deputy Director of the Fangchenggang Municipal Health Commission, visited Genecradle Therapeutics for inspection and exchange. The delegation also included He Yaohai, Vice President of Fangchenggang First People's Hospital, and Xuan Yide, Vice President of Fangchenggang Maternal and Child Health Hospital. The two sides held thorough discussions on promoting cross-regional collaboration in cutting-edge gene technologies and facilitating the precise alignment of clinical resources with scientific and technological innovation strengths.
As a representative enterprise of the Beijing E-Town Biomedical Innovation Cluster, Genecradle Therapeutics systematically presented its full-chain layout in the field of gene therapy to the visiting team. Covering the construction of core technology platforms, R&D breakthroughs in cutting-edge areas such as rare disease gene therapy and vector process development, as well as phased achievements in clinical translation and industrialization, the presentation demonstrated the profound technical accumulation and industrial innovation vitality of Beijing E-Town in the innovative drug sector. The delegation conducted an on-site tour of Genecradle Therapeutics, gained an in-depth understanding of the technical strengths of gene drugs from laboratory to clinic, and spoke highly of Genecradle Therapeutics' technical capabilities in biomedical innovation.
At the symposium, Deputy Director Huang Zhonghui introduced the unique geographical advantages and medical resource endowment of the International Medical Open Pilot Zone. As a frontline gateway for China's opening-up and cooperation with ASEAN, the pilot zone enjoys inherent advantages in cross-border medical collaboration and the pooling of international clinical resources, providing broad application scenarios for innovative medical technologies. Participants conducted in-depth discussions on core topics including the conditions for clinical translation and implementation of gene therapy projects, cross-border clinical resource collaboration models, and pathways for ASEAN-oriented international medical cooperation.
The two sides agreed that Beijing E-Town's strengths in scientific and technological R&D are highly complementary to Fangchenggang's advantages as an international medical open platform. Leveraging the strategic cooperation background of the two regions, the two sides will carry out active exploration in the clinical translation and implementation of gene therapy projects, promote two-way interaction between Beijing E-Town's cutting-edge gene innovation resources and Fangchenggang's ASEAN-oriented international medical resources, and facilitate the effective connection and coordinated development of the biomedical industrial chains of the two regions.